- TheStreet.com•8 days ago
Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.
- Motley Fool•8 days ago
Once biotech M&A heats up again, Acadia, Bluebird, and Jazz could be the first targets on the list, according to our Motley Fool contributors.
bluebird bio, Inc.NasdaqGS
After hours: 50.00-0.45 (-0.89%) as of 6:48 PM EDT
|Bid||49.85 x 500|
|Ask||50.00 x 100|
|52wk Range||35.37 - 169.16|
|Day's Range||48.00 - 50.47|
|Avg Vol (3m)||891,666|
As of 4:00 PM EDT. Market closed.